OptimizeRx (OPRX)
(Delayed Data from NSDQ)
$9.09 USD
-0.07 (-0.76%)
Updated Apr 25, 2024 09:30 AM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for OptimizeRx Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 72 | 62 | 61 | 43 | 25 |
Cost Of Goods | 29 | 23 | 26 | 19 | 9 |
Gross Profit | 43 | 39 | 36 | 24 | 15 |
Selling & Adminstrative & Depr. & Amort Expenses | 69 | 51 | 35 | 26 | 19 |
Income After Depreciation & Amortization | -26 | -12 | 0 | -2 | -4 |
Non-Operating Income | 3 | 1 | 0 | 0 | 0 |
Interest Expense | 1 | 0 | 0 | 0 | 0 |
Pretax Income | -25 | -11 | 0 | -2 | -4 |
Income Taxes | -8 | 0 | 0 | 0 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -18 | -11 | 0 | -2 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -18 | -11 | 0 | -2 | -3 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -24 | -10 | 2 | 0 | -3 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 2 | 2 | 1 |
Income After Depreciation & Amortization | -26 | -12 | 0 | -2 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 17.13 | 17.78 | 17.69 | 14.83 | 13.39 |
Diluted EPS Before Non-Recurring Items | -0.54 | -0.54 | 0.02 | 0.00 | -0.19 |
Diluted Net EPS (GAAP) | -1.03 | -0.64 | 0.02 | -0.15 | -0.23 |
Fiscal Year end for OptimizeRx Corp falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 28.37 | 16.33 | 13.82 | 13.00 |
Cost Of Goods | NA | 10.53 | 6.53 | 5.99 | 5.57 |
Gross Profit | NA | 17.84 | 9.80 | 7.83 | 7.43 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 19.87 | 13.36 | 12.70 | 14.49 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.03 | -3.56 | -4.87 | -7.06 |
Non-Operating Income | NA | 0.12 | 0.69 | 0.72 | 0.67 |
Interest Expense | NA | 1.45 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -11.74 | -2.87 | -4.16 | -6.40 |
Income Taxes | NA | -7.60 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.14 | -2.87 | -4.16 | -6.40 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.14 | -2.87 | -4.16 | -6.40 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 17.77 | 16.64 | 16.99 | 17.10 |
Diluted EPS Before Non-Recurring Items | NA | 0.11 | -0.10 | -0.21 | -0.34 |
Diluted Net EPS (GAAP) | NA | -0.25 | -0.17 | -0.24 | -0.37 |